Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Executives Buy Over $6M Of 5 Penny Stocks

Author: Lisa Levin | February 08, 2022 09:00am

Although gold prices traded slightly lower to below $1,820 an ounce on Tuesday ahead of US inflation data due later in the week, there were a few notable insider trades.

When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

Evolving Systems

  • The Trade: Evolving Systems, Inc. (NASDAQ:EVOL) 10% owner Evolving Systems acquired a total of 12,598 shares at an average price of $1.85. To acquire these shares, it cost $23.25 thousand.
  • What’s Happening: Evolving Systems recently reported a strategic collaboration with Zain Saudi Arabia to deliver a key component of its new Loyalty offering.
  • What Evolving Systems Does: Evolving Systems Inc provides real-time digital engagement solutions and services. It offers services to the wireless carrier and consumer financial services markets.

Cyclo Therapeutics

  • The Trade: Cyclo Therapeutics, Inc. (NASDAQ:CYTH) CEO N. Scott Fine acquired a total of 10,334 shares at an average price of $3.58. The insider spent around $37 thousand to buy those shares.
  • What’s Happening: Cyclo Therapeutics recently filed for U.S. patent titled 'Methods For Treating Alzheimer's Disease.'
  • What Cyclo Therapeutics Does: Cyclo Therapeutics Inc is a clinical-stage biotechnology firm. The company develops cyclodextrin-based products for the treatment of disease.

Also check this: PayPal And 3 Other Stocks Bought By Insiders

Genworth Financial

  • The Trade: Genworth Financial, Inc. (NYSE:GNW) Director Robert Restrepo Jr acquired a total of 50,000 shares at an average price of $3.93. To acquire these shares, it cost $196.65 thousand.
  • What’s Happening: The company recently posted upbeat quarterly earnings.
  • What Genworth Financial Does: Genworth Financial is a diversified insurance holding company that provides various mortgage and life insurance products.

loanDepot

  • The Trade: loanDepot, Inc. (NYSE:LDI) CEO Anthony Li Hsieh acquired a total of 1,584,611 shares at an average price of $3.68. The insider spent $5.83 million to buy those shares.
  • What’s Happening: LoanDepot recently reported worse-than-expected Q4 EPS results.
  • What loanDepot Does: loanDepot Inc was incorporated in Delaware on July 10, 2015. The Company provides nonbank consumer lending solutions for individuals in the United States.

Regulus Therapeutics

  • The Trade: Regulus Therapeutics Inc. (NASDAQ:RGLS) Chief Scientific Officer Denis Drygin acquired a total of 23,314 shares at an average price of $0.23. The insider spent $5.36 thousand to buy those shares.
  • What’s Happening: Regulus Therapeutics recently completed a pre-investigational new drug (Pre-IND) meeting with the FDA to obtain input on the Company's RGLS8429 for Autosomal Dominant Polycystic Kidney Disease (ADPKD).
  • What Regulus Therapeutics Does: Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases.

Posted In: CYTH EVOL GNW LDI RGLS

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist